Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
immunoglobulin therapy |
| gptkbp:activeIngredient |
gptkb:human_immunoglobulin_G
|
| gptkbp:administrationFrequency |
biweekly
weekly |
| gptkbp:approvalYear |
2010
|
| gptkbp:ATCCode |
gptkb:J06BA01
|
| gptkbp:concentration |
20% immunoglobulin
|
| gptkbp:contraindication |
anaphylactic reaction to immunoglobulins
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:form |
gptkb:water
|
| https://www.w3.org/2000/01/rdf-schema#label |
Hizentra
|
| gptkbp:indication |
gptkb:chronic_inflammatory_demyelinating_polyneuropathy
immunodeficiency |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:CSL_Behring
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:shelfLife |
30 months
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue headache back pain injection site reaction |
| gptkbp:storage |
2-8°C
|
| gptkbp:bfsParent |
gptkb:CSL_Limited
|
| gptkbp:bfsLayer |
6
|